Trial Profile
Prospective descriptive study of the infectious aetiology of otitis media and of nasopharyngeal bacterial flora of children in New Zealand under two different pneumococcal vaccination schedules. Multicentre Trial of under 3 year old children at Starship, Counties Manukau and Canterbury DHB's.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Acronyms OMIVI
- Sponsors GlaxoSmithKline; GSK
- 08 Jun 2016 Status changed from not yet recruiting to completed.
- 27 Apr 2011 New trial record